Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efalizumab.

Keri Wellington1, Caroline M Perry

  • 1Adis International Inc., Yardley, Pennsylvania 19067, USA. demail@adis.com

American Journal of Clinical Dermatology
|April 1, 2005
PubMed
Summary
This summary is machine-generated.

Efalizumab effectively treats moderate-to-severe plaque psoriasis by inhibiting T-cell activation. This monoclonal antibody significantly reduces disease activity and improves quality of life with good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

Defining the Potential for Disease Modification in Atopic Dermatitis.

American journal of clinical dermatology·2026
Same journal

Atopic Dermatitis: New Targets and Emerging Systemic Therapies.

American journal of clinical dermatology·2026
Same journal

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

American journal of clinical dermatology·2026
Same journal

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same journal

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026
Same journal

What's New in Photoprotection?

American journal of clinical dermatology·2026
See all related articles

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • T-cell activation plays a key role in psoriasis pathogenesis.
  • Novel therapeutic targets are needed for psoriasis treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of efalizumab in patients with chronic, moderate-to-severe plaque psoriasis.
  • To assess the impact of efalizumab on disease activity and quality of life.

Main Methods:

  • Randomized, double-blind, placebo-controlled trials were conducted.
  • Efalizumab (1.0 mg/kg) was administered subcutaneously once weekly for 12 weeks.
  • Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were used for assessment.

Related Experiment Videos

Main Results:

  • Efalizumab significantly reduced disease activity compared to placebo, with 22.4-38.9% of patients achieving >=75% PASI decrease.
  • Treatment efficacy was sustained over 15 months.
  • Significant improvements were observed in all DLQI domains, indicating enhanced quality of life.

Conclusions:

  • Efalizumab is an effective treatment for chronic, moderate-to-severe plaque psoriasis.
  • The drug demonstrates a favorable safety profile with manageable adverse events.
  • Efalizumab offers a valuable therapeutic option for improving patient outcomes in psoriasis.